Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation

@article{Hoen2017DataEE,
  title={Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation},
  author={E. '. 't Hoen and P. Boulet and Brook K. Baker},
  journal={Journal of Pharmaceutical Policy and Practice},
  year={2017},
  volume={10}
}
The challenge of providing access to high-priced patented medicines is a global problem affecting all countries. A decade and a half ago the use of flexibilities contained in the World Trade Organization Agreement on Trade Related Aspects of Intellectual Property Rights, in particular compulsory licensing, was seen as a mechanism to respond to high-price medicines for the treatment of HIV/AIDS in low- and middle-income countries. Today a number of upper-income European Union (EU) Member States… Expand
Global equitable access to vaccines, medicines and diagnostics for COVID-19: The role of patents as private governance
TLDR
It is argued that the extent of control currently given to patent holders for COVID-19 must be questioned and that patents have significant implications for healthcare acting as private governance tools over patented inventions. Expand
Role of Medicine Patent Pool (MPP) in Resolving Conflict between Patents and Access to Essential Medicines
This paper analyses the issue from both international intellectual property law and access to medicine with reference to contributions made by Medicine Patent Pool (MPP), an alternate model ofExpand
The test data provision of USMCA: A potential to promote or negate the timely access to genetically engineered biologics?
With the adoption of the World Trade Organization’s (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (henceforth, TRIPS), the WTO members agreed to provide a minimum level ofExpand
Importance of the intellectual property system in attempting compulsory licensing of pharmaceuticals: a cross-sectional analysis
  • K. Son
  • Business, Medicine
  • Globalization and Health
  • 2019
TLDR
Evidence of an association between attempting compulsory licensing and matured patent systems is provided by demonstrating that countries with a mature patent system were more likely to utilize compulsory licensing of pharmaceuticals. Expand
Strategic procurement and international collaboration to improve access to medicines
TLDR
Examples of the experiences of countries in the World Health Organization's European Region in improving the efficiency of procurement of medicines are provided and how international collaboration could help improve individual country’s efforts are explained. Expand
Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too
Law Centre for Health and Life, Faculty of Law, University of Amsterdam, Amsterdam, The Netherlands WHO Collaborating Centre for Governance, Accountability, and Transparency in the PharmaceuticalExpand
Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?
ABSTRACT Background: Increased coverage with antiretroviral therapy for people living with HIV in low- and middle-income countries has increased their life expectancy associated with non-HIVExpand
Similar or the Same? Why Biosimilars are not the Solution
TLDR
How the biologics production process distorts the trade-offs that traditionally guided both patent protection and regulatory exclusivities is explained: disclosure as a key condition for benefiting from the corresponding monopoly position. Expand
Evidence Underlying Policy Proposals for Sustainable Anticancer Drug Prices: A Systematic Review.
TLDR
The findings suggest that despite the urgency of the search for proposals that lead to sustainable drug prices, careful and structured testing of proposals is needed because the implications for access to drug treatment can be substantial. Expand
Can International Patent Law Help Mitigate Cancer Inequity in LMICs?
TLDR
Some impediments to effective use of existing policies to promote access to treatment and prevention measures in LMICs are highlighted and recommendations about next steps are offered. Expand
...
1
2
...

References

SHOWING 1-10 OF 58 REFERENCES
'Government Patent Use': A Legal Approach To Reducing Drug Spending.
TLDR
It is proposed that the federal government invoke its power under an existing "government patent use" law to reduce excessive prices for important patent-protected medicines. Expand
Unfair competition under the TRIPS agreement: protection of data submitted for the registration of pharmaceuticals.
  • C. Correa
  • Economics, Medicine
  • Chicago journal of international law
  • 2002
TLDR
National legal practices with respect to protection of test data before the adoption of the TRIPS Agreement are described and the legal means that states may adopt to provide protection against commercial use of such data are discussed. Expand
Ending Drug Registration Apartheid: Taming Data Exclusivity and Patent/Registration Linkage
  • Brook K. Baker
  • Economics, Medicine
  • American Journal of Law & Medicine
  • 2008
TLDR
Obtaining monopoly rights in emerging markets in Latin America, Asia, and even Africa could help the pharmaceutical industry weather the storm of increased consumer, business, and government blow-back against supra-competitive drug prices charged in rich country markets. Expand
The Agreement on Trade-Related Aspects of Intellectual Property Rights Flexibilities on Intellectual Property Enforcement: The World Trade Organization Panel Interpretation of China-Intellectual Property Enforcement of Criminal Measures and Its Implications
Criminal procedure is one of the three major points in the China-Intellectual Property (IP) case brought about by the United States. A number of experts believed that United States failed on thisExpand
Estimated generic prices for novel treatments for drug-resistant tuberculosis
TLDR
Competitive large-scale generic manufacture could allow supplies of treatment for 5-10 times more MDR-TB cases within current procurement budgets. Expand
World Intellectual Property Organization
Economic development throughout the world is linked increasingly with the expansion and protection of intellectual property rights (IPR). Weak or inconsistent patent, trademark and copyright lawsExpand
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
TLDR
Generic TKIs could allow significant savings and scaling-up of treatment globally, for over 1 million eligible patients, according to current high prices. Expand
Discursive Democracy in and around the World Trade Organization The Making of the Declaration on the TRIPS Agreement and Public Health (Doha Declaration)
Deliberative democratic theory has become prominent in international relations. This thesis applies Dryzek's theory of transnational discursive democracy in order to examine the role of global civilExpand
Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
Large-scale manufacture of treatment to cure hepatitis C virus (HCV) is feasible, with target prices of US$100–$250 per 12-week treatment course. These low prices could make widespread access to HCVExpand
...
1
2
3
4
5
...